Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN)

Clinical Biochemistry

Volumn 38, Issue 3, 2005, Pages 223-228

  Atanasova, Srebrena Y ^a,b   Von Ahsen, Nicolas ^a   Toncheva, Draga I ^b   Dimitrov, Tzvetan G ^b   Oellerich, Michael ^a   Armstrong, Victor W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Balkan endemic nephropathy (BEN); Bulgarian population; CYP2D6; CYP3A4 promoter polymorphism; CYP3A5

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5;

ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENDEMIC DISEASE; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RISK ASSESSMENT;

EID: 13544254391     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2004.12.002     Document Type: Article

References (24)

1. A. Puchlev, T. Dimitrov, I. Dinev, and D. Doichinov Clinical investigations in patients with endemic nephropathy S. Strahinjic V. Stefanovic Endemic (Balkan) nephropathy 1979 University press Ni 7 10
2. V. Stefanovic Balkan endemic nephropathy: a need for novel aetiological approaches Q. J. Med. 91 1998 457 463
3. W. Orem, G. Feder, and R. Finkelnman A possible link between Balkan endemic nephropathy and the leaching of toxic organic compounds from Pliocene lignites by groundwater Int. J. Coal Geol. 40 1999 3237 3252
4. D. Toncheva, T. Dimitrov, and S. Stojanova Etiology of Balkan Endemic Nephropathy: a multifactorial disease Eur. J. Epidemiol. 14 1998 389 394
5. W. Nebert, A. McKinnon, and A. Puga Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer DNA Cell Biol. 15 1996 273 280
6. S. Rendic, and F. Di Carlo Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors Drug Metab. Rev. 29 1997 413 580
7. L. Steijns, and J. Van Der Weide Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication Clin. Chem. 44 1998 914 917
8. I. Nikolov, I. Chernozemsky, and J. Idle Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor IARC Sci. Publ. 115 1991 289 296
9. B. Haehner, J. Gorski, and M. Vandenbranden Bimodal distribution of renal cytochrome P450 3A activity in humans Mol. Pharmacol. 50 1996 52 59
10. T. Rebbeck, J. Jaffe, A. Walker, A. Wein, and S. Malkowicz Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J. Natl. Cancer Inst. 90 1998 1225 1229
11. N. von Ahsen, M. Richter, C. Grupp, B. Ringe, M. Oellerich, and V. Armstrong No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients Clin. Chem. 47 2001 1048 1052
12. P. Kuehl, J. Zhang, and Y. Lin Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat. Genet. 27 2001 383 391
13. E. Hustert, M. Haberl, and O. Burk The genetic determinants of the CYP3A5 polymorphism Pharmacogenetics 11 2001 773 779
14. R. Givens, Y. Lin, and A. Dowling Cyp3a5 genotype predicts renal Cyp3a activity and blood pressure in healthy adults J. Appl. Physiol. 95 2003 1297 1300
15. L. Djukanovic, D. Bukvic, I. Maric, R. Cukuranovic, M. Vukomanovic, and S. Glogovac Open questions on Balkan nephropathy Nephrol. Dial. Transplant. 16 Suppl. 6 2001 27 29
16. M. Heim, and U. Meyer Genotyping of poor metabolizers of debrisoquine by allelle-specific PCR amplification Lancet 336 1990 529 532
17. J. Abramson, and P. Gahlinger Computer programs for epidemiologists: PEPI version 3 1999 Brixton Books Llanindloes, Powys, Wales
18. C. Sachse, J. Brockmöller, S. Bauer, and I. Roots Cytochrome P450 2D6 variants in Caucasian population: allele frequencies and phenotypic consequences Am. J. Hum. Genet. 60 1997 284 295
19. M. Dahl, I. Johansson, M. Palmertz, M. Ingelman-Sundberg, and F. Sjoqvist Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population Clin. Pharmacol. Ther. 51 1992 12 17
20. R. Lovlie, A. Daly, G. Matre, A. Molven, and V. Steen Polymorphisms in CYP2D6 duplication-negative individuals with ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 11 2001 45 55
21. I. Koch, R. Weil, and R. Wolbold Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA Drug Metab. Dispos. 30 2002 1108 1114
22. O. Burk, and L. Wojnowski Cytochrome P450 3A and their regulation Naunyn-Schmiedeberg's Arch. Pharmacol. 369 2004 105 124
23. G. Murray, T. Barnes, H. Sewell, S. Ewen, W. Melvin, and M. Burke The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extra-hepatic tissues with a monoclonal antibody to human cytochrome P-450 Br. J. Clin. Pharmacol. 25 1988 465 475
24. H. Zepnik, A. Pahler, U. Schauer, and W. Dekant Ochratoxin A-induced tumor formation: is there a role of reactive ochratoxin A metabolites? Toxicol. Sci. 59 2001 59 67